Highest-materiality recent filing
Doximity Q4 GAAP net income sinks 69%; guides ~4% FY2027 revenue growth; new CFO and President
FY2026 revenue $644.9M (+13% YoY); GAAP net income $196.1M (down 12% YoY, margin 30.4%).
Doximity CFO Anna Bryson resigns; interim CFO continues; guidance reaffirmed
Anna Bryson's resignation as CFO accepted April 13, 2026, following medical leave since Feb 5, 2026.
Doximity Q3 revenue up 10% to $185M, guides Q4 $143-144M, authorizes $500M buyback
Revenue $185.1M (+10% YoY); net income $61.6M (33% margin) vs $75.2M (45% margin) YoY.
Doximity reports Q2 revenue $168.5M (+23% YoY), adjusted EBITDA $100.8M; raises FY guidance
Revenue $168.5M vs $136.8M YoY, up 23%; non-GAAP net income $90.0M (53.4% margin).
Doximity Q1 revenue $145.9M (+15%), adj. EBITDA $79.8M (+21%), raises FY guidance
Revenue $145.9M (+15% YoY); net income $53.3M (36.5% margin); non-GAAP EPS $0.36.
Doximity reports Q4 revenue up 17% YoY to $138.3M; guides FY2026 revenue $619-631M
Q4 revenue $138.3M (+17% YoY); subscription revenue $131.9M (+17% YoY).
Doximity Q3 revenue up 25% YoY to $168.6M; adjusted EBITDA up 39%
GAAP net income $75.2M ($0.37 diluted EPS) vs $48.0M YoY; non-GAAP net income $91.4M ($0.45) vs $58.5M.
Doximity Q2 FY2025 revenue $136.8M, up 20% YoY; net income up 44%; raises FY guidance
Revenue $136.8M (+20% YoY); net income $44.2M (+44%); non-GAAP diluted EPS $0.30.
Doximity Q1 revenue $126.7M (+17% YoY), net income +46%; FY revenue guidance $514-523M
GAAP EPS $0.21 vs $0.13 YoY; non-GAAP EPS $0.28 vs $0.19.
Doximity beats Q4 estimates; guides FY2025 revenue $506-518M; authorizes $500M buyback
Q4 revenue $118.1M (+6% YoY), subscription $112.7M (+9%); GAAP EPS $0.20, non-GAAP $0.25.
Doximity Q3 revenue $135.3M (+17% YoY), net income $48.0M; raises FY2024 guidance
Revenue $135.3M (up 17% YoY); net income $48.0M (35.4% margin) vs $33.5M (29.0%) YoY.
Doximity Q2 revenue $113.6M (+11% YoY), adj EBITDA margin 48%; guides FY rev $460-472M
Revenue $113.6M, up 11% YoY; net income $30.6M (27% margin); diluted EPS $0.15, non-GAAP $0.22.
Doximity Q1 revenue $108.5M (+20% YoY); workforce reduction of ~100 employees
Revenue $108.5M (+20% YoY); adjusted EBITDA $46.6M (+39% YoY); non-GAAP EPS $0.19 vs $0.14.
Doximity targets $1B revenue by FY2028, adds $200M buyback, unveils AI tools
Long-term target: >$1B revenue in fiscal 2028; adjusted EBITDA margins of 45%+.
Doximity Q4 revenue $111M (+18% YoY); FY2024 guidance $500-506M
Q4 revenue $111.0M (+18% YoY); net income $30.7M (27.6% margin); adj. EBITDA $48.9M (44.1% margin).
Doximity Q3 revenue up 18% to $115.3M; cash flow up 85%; FY24 revenue >$500M
Revenue $115.3M, +18% YoY.
Doximity Q2 revenue $102.2M (+29% YoY), beats; net income down; $70M buyback authorized
Q2 revenue $102.2M (+29% YoY); net income $26.3M (26% margin) vs $36.1M (45% margin) year ago.
Doximity Q1 FY2023 revenue $90.6M (+25% YoY); appoints Phoebe Yang to board
Revenue $90.6M (+25% YoY); GAAP net income $22.4M (25% margin) vs $26.3M (36%) YoY.
Doximity Q4 revenue $93.7M (+40% YoY), FY2022 rev $343.5M (+66%); guides FY23 rev $454-458M
Q4 revenue $93.7M (up 40% YoY); net income $36.7M (39% margin); adjusted EBITDA $39.4M (42% margin).
Doximity Q3 revenue $97.9M (+67% YoY), net margin 57%, guides FY23 rev ~$450M
Revenue $97.9M (+67% YoY); net income $55.6M (57% margin); non-GAAP diluted EPS $0.29.
Doximity Q2 FY2022 revenue $79.4M (+76% YoY); net income $36.1M; lock-up expiry Nov 12
Revenue $79.4M, up 76% YoY; net income $36.1M (45% margin); non-GAAP net income $41.6M (52% margin).
Doximity Q1 revenue $72.7M (+100% YoY); net income margin 36%
Revenue $72.7M, up 100% YoY; net income $26.3M (36% margin) vs $1.5M a year ago.
Additionally, the Company announced the appointment of Steven L. Zatz, M.D. as President of the Company, effective May 13, 2026.
On May 13, 2026, Doximity, Inc. (the “Company”) announced the appointment of Matthew Sonefeldt as Chief Financial Officer of the Company, effective May 13, 2026.
On June 10, 2025, Dr. Nathan Gross notified Doximity, Inc. (the “Company”) that he will step down from his role as Chief Strategy Officer to become an advisor to the Company, effective June 16, 2025.
On May 16, 2023, Doximity announced the appointment of Craig Overpeck as Senior Vice President, Commercial Operations.
On August 2, 2022, the Board appointed Phoebe L. Yang Watkin to serve as a Class III director of the Board, filling the vacancy created by the departure of Dr. Kliman from the Board, effective immediately, until the annual meeting of the Doximity’s stockholders to be held in calendar 2024
On August 2, 2022, Gilbert Kliman, M.D. informed the board of directors (the "Board") of Doximity of his intention to step down from his role as a director on the Board, including his membership of the nominating and governance committee and the compensation committees of the Board, effective immediately.
Joseph Kleine will retire from his role as Chief Commercial Officer and will become an advisor to the Chief Executive Officer, starting February 9, 2022.
Max materiality 0.85 · Median 0.75 · Most common event earnings